NCT03795597 - Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2023

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib

Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

DRUG

Busulfan IV

Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

DRUG

Melphalan IV

Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.

Trial Locations (1)

RECRUITING

Loyola University Medical Center, Maywood